Last reviewed · How we verify

Muscle pain — Treatment Landscape & Competitive Intelligence

Muscle pain (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Muscle pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Aleve naproxen Generic (originally Syntex) NSAID Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1 1976-01-01
Immune Support CORTISONE Merck Non-Standardized Plant Allergenic Extract [EPC] 1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Syntex) · 1 drug in Muscle pain
  2. Merck · 1 drug in Muscle pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Muscle pain:

Cite this brief

Drug Landscape (2026). Muscle pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/muscle-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing